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Abstract: The Outcome Measures in Rheumatology workgroup (OMERACT), together with the
Osteoarthritis Research Society International (OARSI) developed the OMERACT-OARSI responder
criteria. These criteria are used to determine if a patient with osteoarthritis (OA) ‘responds’ to
therapy, meaning experiences a clinically relevant effect of therapy. Recently, more clinical OA
trials report on this outcome and most OA trials have data to calculate the number of responders
according to these criteria. A systematic review and meta-analysis were performed on the response
to exercise therapy, compared to no or minimal intervention in patients with hip OA using the
OMERACT-OARSI responder criteria. The literature was searched for relevant randomized trials.
If a trial fit the inclusion criteria, but number of responders was not reported, the first author was
contacted. This way the numbers of responders of 14 trials were collected and a meta-analysis on short
term (directly after treatment, 12 trials n = 1178) and long term (6–8 months after treatment, six trials
n = 519) outcomes was performed. At short term, the risk difference (RD) was 0.14 (95% confidence
interval (CI) 0.06–0.22) and number needed to treat (NNT) 7.1 (95% CI 4.5–17); at long term RD was
0.14 (95% CI 0.07–0.20) and NNT 7.1 (95% CI 5.0–14.3). Quality of evidence was moderate for the
short term and high for the long term. In conclusion, 14% more hip OA patients responded to exercise
therapy than to no therapy.
Keywords: hip osteoarthritis; exercise therapy; responders; meta-analysis
1. Introduction
Hip osteoarthritis (OA) is common cause of disability. In the Netherlands 18.8 out of 1000 men
and 33.3 out of 1000 women suffer from hip OA (prevalence in 2018). Osteoarthritis is the tenth cause
of Disability Adjusted Life Years (DALY’s) in the Netherlands. The economic cost of osteoarthritis in
2017 in the Netherlands was 433.4 million euros, which is 1.4% of total health cost, of which hip OA is
the second cause (knee OA is the first) [1].
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Exercise therapy is an important part of the conservative treatment of patients with hip OA [2,3].
Multiple trials have been conducted to study the effect of exercise therapy in hip OA and most of
them have shown a positive effect of exercise therapy compared to a non-exercise treatment or no
intervention [4,5]. In most of these trials, pain, function, or patient global assessment were the primary
outcomes. Combining trials for meta-analysis can often be challenging because of the use of different
outcomes and definitions of treatment success.
An Outcome Measures in Rheumatology (OMERACT) workgroup have put effort into
synchronizing future trial outcomes by defining core outcome sets (COS) [6]. After an extensive
procedure of discussion and polling, they stated that clinical trials in knee, hip, and hand OA should
measure at least four domains: pain, disability, patient global assessment, and for long-term trials,
also joint imaging. This was updated in 2019 by adding quality of life and adverse effects to the
COS [7]. Subsequently, this OMERACT workgroup together with the Osteoarthritis Research Society
International (OARSI) formulated a set of responder criteria [8]. These criteria combine three of the
core outcomes: pain, disability, and patient global assessment, in one outcome to define response
or non-response to treatment. Some trials already reported on this combined outcome, concerning
the effect of exercise therapy in patients with hip OA [9]. Though, trials not reporting this outcome
did often measure pain, disability, and patient global assessment separately, and are therefore able to
calculate this outcome in their existing dataset.
In 2016, our department was asked by the National Health Care Institute of the Netherlands to
update the existing evidence of three Cochrane reviews on the effect of exercise therapy, compared
to no or minimal intervention in patients with hip and knee OA [4,5,10]. The Minister of Health,
Welfare, and Sports wanted to evaluate if exercise therapy for patients with hip and knee OA should
be reimbursed by the basic health insurance in the Netherlands. Therefore, we conducted a systematic
review on the effect of exercise therapy in hip OA, compared to no/minimal intervention. Fifteen studies
were included, and four studies reported on responders, although only one used the OMERACT-OARSI
set of responder criteria [11].
Although this systematic review and meta-analysis showed moderate quality evidence in the
short term and high quality evidence in the long term for an effect of exercise therapy compared to no
or minimal intervention on pain and function in hip OA, we were interested in this combined outcome
of response to treatment. Evaluating the effect of a therapy by looking at number of responders is
a very intuitive way. It is closer to practice, since it does not give an average change in a group of
patients but a binary outcome per patient and therefore results are easier to interpret for patients and
providers of care than continuous outcomes [12]. By using the OMERACT-OARSI responders criteria,
we are able to combine data of different studies in an uniform and well-grounded manner [8].Therefore,
the aim of this study was to evaluate the existing evidence of the effect of exercise therapy in patients
with hip OA, when ‘effect’ is formulated as in the OMERACT-OARSI set of responder criteria.
2. Materials and Methods
We performed a secondary analysis on the data of the original systematic review (described below).
2.1. Search Strategy
We updated the two Cochrane reviews on the effect of exercise therapy in patients with hip OA [4,5].
Therefore, we performed a literature search with the same search terms from these reviews from the
date of their last search until March 2019. Main search terms (and derivatives) were osteoarthritis,
hip (joint), knee (joint), exercise, sport, physical therapy, rehabilitation, and randomized controlled trials.
Literature sources were Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase,
Cumulative Index to Nursing and Allied Health Literature (CINAHL), PEDro (Physiotherapy Evidence
Database), and Web of Science. Detailed information can be found in Supplementary Material S1.
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2.2. Study Selection
Randomized trials were selected if they fulfilled the following criteria: patients were >18 years
old with clinical and/or radiological hip osteoarthritis, the intervention was an active form of exercise
therapy under supervision of a (physical) therapist, the intervention was not part of a multidisciplinary
or multimodal program and was evaluated as a standalone intervention, the intervention in the control
group was usual care (e.g., medication and/or education), and no treatment or waiting list. Studies with
control interventions as hot packs, transcutaneous electrical nerve stimulations, and ultrasound were
excluded. Furthermore, for this analysis, the outcomes enable us to calculate responders using
the OMERACT-OARSI criteria at short term (directly after end of treatment) and/or at long term
(6–8 months after end of treatment).
2.3. Risk of Bias Assessment
Risk of bias was assessed with the Cochrane risk of bias tool [13]. This tool has seven
domains; random sequence generation, allocation concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and other
bias. Each domain is assigned a low, high, or unclear risk of bias. We also assigned studies an
overall risk of bias. If a study used a random sequence generation, correct allocation concealment,
and intention-to-treat-analysis, it was considered as low risk of bias. A high risk of bias was assigned if
less than three domains had a low risk of bias. All other studies were considered to have a moderate
risk of bias.
2.4. Data Collection
We extracted data on study characteristics: patient population, type of intervention, and type
of control group. We also extracted data on results for multiple outcomes concerning responders.
If no data was presented on number of responders according to the OMERACT-OARSI criteria,
the corresponding author was contacted. We asked the authors whether they were able and willing
to calculate the number of responders in the intervention group and control group, or whether they
would be willing to provide us with the data to enable us to calculate these numbers.
Selection of studies, risk of bias assessment and data extraction was done by two review authors
(A.P.V., C.H.T., E.A.E.R., L.M.v.R., or M.v.M.) independently. In case of disagreement and if no
consensus could be reached, a third review author (A.P.V. or M.v.M.) made the final decision.
2.5. Outcome
The OMERACT-OARSI set of responder criteria uses pain, function, and patient global assessment
to define response to therapy. Response is defined as an improvement in pain or in function ≥ 50%
and absolute change ≥ 20, or improvement in at least two of the three following: pain ≥ 20% and
absolute change ≥ 10; function ≥ 20% and absolute change ≥ 10; and patient’s global assessment
≥ 20% and absolute change ≥ 10 [8]. Since not all studies collected an outcome of patient global
assessment, we agreed to calculate the number of responders with only pain and function in only
these studies. This meant that if a patient does not qualify as a responder based on pain and function
data, we considered this participant a non-responder. Theoretically, this participant could be a
responder if global assessment data would have been available. For outcomes using a Likert scale [14],
we converted it to a 0–100 scale. This allowed us to calculate an absolute and relative change from
baseline. If necessary, scales were inverted, ensuring that higher scores corresponded with more
severe symptoms. If data on pain and/or function were missing, we considered this participant
a non-responder.
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2.6. Analysis
A meta-analysis was performed using a random-effect model in Review Manager 5.3 for short
and long term. A risk difference (RD), number needed to treat and 95% confidence interval (95% CI)
were calculated.
Finally, the quality of evidence was determined using the GRADE(Grading of Recommendations,
Assessment, Development and Evaluations) approach [15]. Quality was considered high and was
subsequently lowered to moderate, low, or very low if one or more of these criteria applied: (a) study
limitations: >25% of patients are from studies with an overall high risk of bias; (b) inconsistency:
statistical heterogeneity I2 > 40% or <75% of patients show results in the same direction; (c) indirectness:
results are not suitable to extrapolate to the target population according to expert authors (J.R. and
S.M.A.B.-Z.); (d) imprecision: <400 patients; or (e) other: like publication bias or ‘fatal flaw’ (for example
selective loss of follow-up).
Sensitivity analysis was done by excluding participants with missing data from analysis
(complete cases) and by excluding studies in which no global assessment outcome was available.
3. Results
3.1. Selection of Studies
Originally, we performed a review about the effect of exercise therapy in hip and knee OA,
therefore, the flowchart shows the references of knee OA during the beginning of the selection process,
see Figure 1. Nine out of 12 studies on hip OA from the Cochrane reviews were included; three studies
were excluded because they did not fulfill our criteria. Our additional literature search resulted in
an extra eight studies. In total 17 studies were potentially eligible for the current analysis. Of these
17 studies, only one study presented results of responders according to OMERACT-OARSI responder
criteria. We contacted the authors of the other 16 studies of which 13 responded and were willing to
provide us the data on responders. Finally, for this analysis we used the data from 14 studies in total,
including a total of 1242 participants.
3.2. Study Characteristics
The characteristics of these 14 studies are presented in Table 1. All studies included patients with
symptoms (clinical hip OA with or without signs of radiological OA) and most studies (12 out of 14)
used the ACR (American College of Radiology) criteria (clinical and/or radiological) to include patients.
Group size varied from 14 to 102 patients. Interventions were mostly exercises on land; only one used
aquatic exercises. Seven interventions were group-based, five individually-based, and two studies did
not specify this. Interventions lasted from 5–12 weeks. Control groups existed of education, medication,
waiting list, GP(general practice care), or usual care. All studies measured pain and function, only five
studies also measured global assessment.
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Table 1. Study characteristics.
Study Population Intervention Control Measurements Overall Risk of Bias #
V Baar 1998 [16]
N = 81 Clinical ACR
Exercise (n = 35). Individual
physiotherapy program (12 weeks,
1–3×/week, 30-min sessions) + GP
education + medication if necessary.
GP education + medication if
necessary (n = 33).
After treatment:
Function: IRGL
Pain: VAS pain past week
Global assessment: global perceived effect
8-point Likert scale
Low
Hopman-Rock 2000 [17]
N = 34 ACR
Exercise (n = 14). Group sessions
(6 weeks, 1×/week, 60-min classes) +
1×/week education.
Waiting list (n = 20).
After treatment and 6 months after treatment:
Function: IRGL-mobility
Pain: VAS pain last month
Global assessment: -
High
Stener-Victorin 2004 [18]
N = 45
Radiological ACR
Patients on waiting list for
hip replacement
Aquatic exercise (n = 15). Group session
(5 weeks, 2×/week, 30 min) + education.
Two group meetings lasting 2 h each
concerning hip anatomy, disease process,
and advice on physical activities.
Education (n = 15). Two group
meetings lasting 2 h each concerning
hip anatomy, disease process,
and advice on physical activities.
After treatment and 6 months after treatment:
Function: Disability Rating Index
Pain: VAS pain during motion
Global assessment: -
High
Tak 2005 [19]
N = 109 Clinical ACR
Exercise (n = 55). Group session
(8 weeks, 1×/week strengthening + home
program, 60-min) + education.
GP care (n = 54).
After treatment and 3 months after treatment:
Function: Sickness Impact Profile – mobility
Pain: VAS pain last month
Global assessment: -
High
Fernandes 2010 [20]
N = 109
Radiological ACR and
symptoms (Harris Hip
Score 60–95)
Exercise (n = 55). Individually based
(12 weeks, 2×/week) + patient education. Patient education (n = 54).
After treatment and 6 months after treatment:
Function: WOMAC
Pain: WOMAC
Global assessment: -
Low
Juhakoski 2011 [21]
N = 120
Radiological and clinical
ACR, K–L grade >1.
Exercise (n = 60). Group sessions
(12 weeks,1×/week, 45 min, + 4 booster
sessions 1 year later) + GP care
GP care (n = 60).
After treatment:
Function: WOMAC
Pain: WOMAC
Global assessment: -
Low
French 2013 [22]
N = 88
Radiological and clinical
ACR
Exercise (n = 45). Individually provided
‘standardized’ exercise program (8 weeks,
6–8 sessions, 30-min) + daily home
exercise program (aerobic
walking/cycling/swimming 30 min)
Waiting list (n = 43).
After treatment:
Function: WOMAC-PF
Pain: NRS
Global assessment: global rating of change
7-point Likert scale
Low
Abbott 2013 [9]
N = 45 Clinical ACR
Exercise (n = 22). Individually provided
by physiotherapist, 50 min (9 weeks, 7
sessions + 2 booster sessions week 16).
GP care (n = 23).
8 months after treatment: Function: WOMAC
Pain: WOMAC
Global assessment: global rating of change
Low
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Table 1. Cont.
Study Population Intervention Control Measurements Overall Risk of Bias #
Villadsen 2014 [23]
N = 84
Scheduled for hip
replacement because of
symptomatic OA
Exercise (n = 43). Neuromuscular
training (8 weeks, 2×/week, 60 min) +
education (written information, also on
various exercises)
Education (n = 41). Written
information, also on various exercises
After treatment:
Function: HOOS
Pain: HOOS
Global assessment: -
Low
Krauss 2014 [24]
N = 140 Clinical ACR
Exercise (n = 71). Group sessions
(12 weeks, 1×/week, 60–90 min, 2×/week
home exercises, 30–40 min).
Control (n = 69). No intervention
After treatment:
Function: WOMAC
Pain: WOMAC
Global assessment: -
Low
Teirlinck 2016 [25]
N = 203 Clinical ACR
Exercise (n = 101). Individual therapy
(12 weeks, 12 sessions, 3 booster sessions
in 5th, 7th, and 9th month) + GP care.
GP care (n = 102).
After treatment and 6 months after treatment:
Function: HOOS
Pain: HOOS
Global assessment: Recovery 7-point Likert
scale
Low
Hermann 2016 [26]
N = 80
Scheduled for hip
replacement
Exercise (n = 40). Pre-operative
progressive explosive resistance training
(10 weeks, 2×/week, 60 min).
Usual care (n = 40).
After treatment:
Function: HOOS
Pain: HOOS
Global assessment: -
Low
Saw 2016 [27]
N = 30
Waiting list for hip
replacement, radiological
and clinical ACR
Exercise (n = 14). Group sessions by
physiotherapist (6 weeks, 1×/week, 120
min) + education.
Usual care (n = 16).
After treatment and 6 months after treatment:
Disability: Health Assessment Questionnaire
- functional disability index
Pain: Brief Pain Inventory
Global assessment: -
Moderate
Bieler 2016 [28]
N = 152
Clinical ACR,
age >60
Exercise (n = 50). Group sessions,
strengthening/resistance exercises
(16 weeks, 3×/week, 60 min).
Counseling + education (n = 52).
After treatment and 8 months after treatment
Function: WOMAC
Pain: WOMAC
Global assessment: 5-point Likert scale
Low
# Low Risk of Bias (RoB): randomization appropriate + concealed + ITT analysis; high RoB: <3 items low risk; moderate RoB: all else. Abbreviations: GP = general practitioner,
ACR = American College of Rheumatology; IRGL = Invloed van Reuma op Gezondheid en Leefwijze (Influence of rheumatic diseases on health and lifestyle); VAS = visual analogue
scale; WOMAC = Western Ontario and McMaster Universities Osteoarthritis Index; K–L = Kellgren and Lawrence score; PF = Physical Function subscale; NRS = numeric rating scale;
HOOS = Hip disability and Osteoarthritis Outcome Score; OA = osteoarthritis. Italic script = time of measurements.
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3.3. Risk of Bias Assessment
Ten studies were considered to have a low risk of bias, one study a moderate risk of bias, and three
studies a high risk of bias, see Table 2. Blinding participants and outcome assessment were not possible
because of the type of intervention. Therefore, almost all studies were considered to have a high risk of
bias on the blinding items. Only one study scored low risk of bias on blinding, as they reported that
participants had no preference for the treatment or control group [28].
Table 2. Risk of bias assessment.
Study
Random
Sequence
Generation
Allocation
Concealment
Blinding of
Participants
and Personnel
Blinding of
Outcome
Assessment
Incomplete
Outcome
Data
Selective
Reporting Other Bias
V Baar 1998 + + - - + ? +
Hopman-Rock 2000 ? ? - - ? ? +
Stener-Victorin 2004 + ? - - - + +
Tak 2005 + ? - - + ? +
Fernandes 2010 + + - - + + +
Juhakoski 2011 + + - - + ? +
French 2013 + + - - + + +
Abbott 2013 + + - - + + ?
Villadsen 2014 + + - - + + +
Krauss 2014 + + - - + + +
Teirlinck 2016 + + - - + + +
Hermann 2016 + + - - + + ?
Saw 2016 + ? - - ? + +
Bieler 2016 + + + + + + +
+ High risk of bias; - low risk of bias; ? unclear risk of bias.
3.4. Meta-Analysis
The meta-analysis showed more responders in the exercise group than in the control group, at short
term (12 trials, n = 1178) and long term (six trials, n = 519), see Figure 2. At short term the percentage of
responders was 30% in the exercise group and 16% in the control group (RD = 0.14, 95% CI 0.06–0.22,
number needed to treat 7.1, 95% CI 4.5–17). At long term the percentage of responders was 26% in the
exercise group and 13% in the control group (RD = 0.14, 95% CI 0.07–0.20, number needed to treat 7.1,
95% CI 5.0–14.3). The quality of the evidence for short term outcome was moderate (downgrading
because of inconsistency) and high for long term outcome (no downgrading).
3.5. Sensitivity Analysis
Complete cases: 95 participants were excluded from the original analysis on short term and
100 participants on long term. Overall risk differences and quality of evidence did not change
(see Supplement, Figure S1).
Global assessment: In this analysis we only included trials that measured patient global assessment,
therefore, the number of responders were calculated according to the full set of OMERACT-OARSI
criteria. Only four studies could be included in the meta-analysis on short term (474 participants
in total) and three studies for long term (350 participants in total). Risk difference on short term
was higher than in the original analysis, although this difference between the two analyses was not
statistically significant: RD = 0.20 (95% CI 0.12–0.27, number needed to treat 5.0) and quality of
evidence was high (no downgrading). On long term, risk difference stayed the same: RD = 0.13
(0.04–0.21, number needed to treat 7.7), but quality of evidence was moderate because of imprecision
(participants < 400), see Supplement, Figure S2.
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4. Discussion
4.1. Main Findings
According to the OMERACT-OARSI responder criteria, more patients respond to exercise therapy
then to no treatment, usual care, medication, or education only at short term (moderate quality of
evidence) and long term (high quality of evidence). The risk difference was 14%, meaning about seven
patients should receive exercise therapy to gain one extra responder.
4.2. Comparison with Literature
To our knowledge, this is the first meta-analysis on responders to exercise therapy in patients
with hip OA. In the Cochrane review on land-based exercise for hip OA, the meta-analysis showed
reduction of pain and physical disability and the authors reported a number needed to treat for
an additional beneficial outcome (NNTB) of six for both outcomes. This is in line with our results,
which is not very surprising since we used the trials of this Cochrane review in our analysis. However,
we included more trials and used a different outcome measure. Compared to numbers needed to
treat (NNT) published for pharmacological interventions in hip OA, an NNT of 7.1 is quite high.
For example, a meta-analysis on steroid injections in the hip in patients with hip OA reported an
NNT of 2.4 (95% CI: 1.7–4.2) at 8 weeks post-intervention using the OMERACT-OARSI responder
criteria (two studies, n = 90) [29]. Another study that pooled two trials on the effect of etoricoxib
and celecoxib compared to placebo in patients with knee or hip OA showed an NNT of 4.3 and 4.9,
respectively, on the outcome of the OMERACT-OARSI responder criteria [30]. Although if exercise
therapy is compared to pharmacologic treatments, it should be noted that the occurrence of adverse
effects is low in exercise therapy [5]. Therefore, our results are in line with earlier found effects of
exercise therapy and with the considerations of existing guidelines to recommend exercise therapy
as non-pharmacological treatment for patients with hip OA [2,3]. After the report of our original
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systematic review, the National Health Care Institute of the Netherland, recommended the Minister of
Health, Welfare, and Sports to reimburse exercise therapy for patients with hip OA [11].
4.3. Strengths and Limitations
Although the reporting of OMERACT-OARSI responders is not so common yet, the data was
available in most trials and because almost all authors were willing to provide us with these data,
we were able to perform a meta-analysis, which has not been done before.
We followed the same methodological steps as used in the Cochrane reviews on exercise (land-based
and water-based) in hip and knee OA, which are considered reliable and evidence-based methods.
We aimed to receive a robust answer to the question of whether exercise therapy is effective in hip OA,
by combining the data of trials in one uniform way. However, using the OMERACT-OARSI responder
criteria in our analysis has some limitations as well. Firstly, the outcomes pain, function, and global
assessment were measured on different scales or questionnaires. Especially differences in scale can
influence the likelihood of a participant being a responder, or not, in different trials. For example,
the WOMAC-pain subscale is measured from 0 (no pain) to 100 (the most pain thinkable) while the
HOOS-pain subscale is measured from 100 (no pain) to 0 (the most pain thinkable). This means that
participants with less pain at baseline have a higher chance of being responder if pain is measured with
WOMAC than with HOOS. To clarify this further: if a participant has a pain score of 30 (scale 0–100)
measured with WOMAC questionnaire at baseline, he would qualify as a responder (if for simplicity
we only look at pain in the first part of the criteria; a change in pain score of ≥50% and absolute change
≥20), if his pain would decrease with at least 20 points. This participant would have a similar pain score
with the HOOS questionnaire around 70 (scale 100–0) and would only qualify as a responder if his pain
score would increase (less pain) with at least 35 points. In our analysis we therefore chose to invert
scales that were measured 100–0, to ensure uniformity. Another example is the use of Likert-scales.
These scales mostly have limited score-options, like 5 or 7. These scales had to be converted to a 0–100
scale to be able to calculate the absolute and relative change, used in the criteria. Nevertheless, then still
only 5–7 possible scores are possible, which makes the changes of being responder different than on a
more continuous scale, like HOOS or WOMAC. Since we contacted the authors ourselves, we were
able to discuss which scales were available in the data and we could uniform this as much as possible.
If more trials report on responders and if these data are subsequently combined in meta-analyses,
reviewers have to be aware of these differences in measurement. Moreover, authors should be aware
of this, by reporting which pain, function, and global assessment outcomes were used and how this
was used in the calculation of number of responders.
Secondly, the previous example also shows that there is a possible ceiling effect. One of the authors
that provided the data to analyze the responders, also did a brief analysis and found that 46 subjects
out of 139 (33% of the population) could not respond to exercise according to the OMERACT-OARSI
criteria because of their light symptoms (data not published, with permission of the author [24]).
This was also noted by the developers of the responder criteria. They suggested a minimal level of
symptoms at entry, if the criteria are used, although no cut-off is determined yet [8].
Thirdly, only a few trials had a measurement on global assessment. We chose to also use the data
of the trials without global assessment. By doing so, we could have underestimated the number of
responders, because some patients who did not qualify as a responder based on pain and function,
could qualify as responder if patient global assessment data was available. Our sensitivity analysis also
showed a possible larger effect (quality of evidence was moderate because of the total sample size and
the difference with the original analysis not statistically significant) if only trials with a measurement
on global assessment were included.
Int. J. Environ. Res. Public Health 2020, 17, 7380 11 of 13
4.4. Implications for Clinical Practice and Research
A priori, we did not specify a minimum for a clinically relevant difference for the risk difference
and/or NNT of responders with hip OA. In the literature, we could not find a recommendation or
consensus about this. One article on knee OA patients treated with doxycycline mentioned a minimal
relevant difference of 20% (NNT five) for the OMERACT-OARSI responder criteria in their study [31].
In comparison with this cut-off and the earlier mentioned pharmacological studies, our effect of exercise
therapy on number of responders seems relatively small. This means for clinical practice, that we
should realize that a large group of patients will not respond to exercise therapy and it therefore
seems important for clinicians to be able to predict which patients are more likely to benefit from
exercise therapy. One study evaluated predictive factors for being a OMERACT-OARSI responder to
exercise therapy and found that hip OA patients with unilateral hip pain, age of ≤58 years, pain of
≥6/10 on a numeric pain rating scale, 40-m self-paced walk test time of ≤25.9 s, and duration of
symptoms of ≤1 year were predictive for response to exercise therapy [32]. In addition, currently a
research collaboration is ongoing to study effect modifiers for exercise therapy in knee and hip OA
with individual participant data meta-analyses in a databank of trials (OA trial bank) [33]. Lastly,
more consensus about the use of scales, measurements, and population (e.g., severity of symptoms)
within these criteria, could improve uniformity and comparability of this measurement.
5. Conclusions
There was moderate quality evidence in the short term (directly after treatment) and high quality
evidence in the long term (6–8 months after treatment) that exercise therapy is effective in patients with
hip OA, when compared to no or minimal intervention, considering the OMERACT-OARSI responder
criteria, although the magnitude of this effect seems relatively small.
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